Selectivity Preparation Status Approval NCT Number
JAK1i Filgotinib II Noninfectious Uveitis NCT03207815
III Ankylosing Spondylitis NCT04483700
III Psoriatic Arthritis NCT04115839
II Lupus Membranous Nephropathy NCT03285711
II Cutaneous Lupus Erythematosus NCT03134222
I Renal Impairment NCT02084199
II Sjogren’s Syndrome NCT03100942
II Inflammatory Bowel Disease NCT03201445
PF04965842 I, III Dermatitis, Atopic NCT03634345
II Plaque Psoriasis NCT02201524
Oclacitinib Approved Atopic dermatitis
JAK2i GSK2586184 I Colitis, Ulcerative NCT02000453
I Systemic Lupus Erythematosus NCT01953835
I Psoriasis NCT01782664
I, II Systemic Lupus Erythematosus NCT01687309; NCT01777256
Pacritinib I Myelofibrosis NCT02765724
II Prostates Cancer NCT04635059
II Acute Myeloid Leukemia (AML) NCT02532010
I Lymphoma, T-Cell, Cutaneous NCT03601819
Lymphoma, T-Cell, Peripheral
Chronic Lymphocytic Leukemia
II Colorectal Cancer NCT02277093
II Leukemia NCT02469415
I, II GVHD NCT02891603
I Non-Small Cell Lung Cancer NCT02342353
Selectivity Preparation Status Approval NCT Number
JAK2i Pacritinib I Non-Small Cell Lung Cancer NCT02342353
I, II Breast Cancer NCT04520269
III COVID19 NCT04404361
JAK3i PF-06651600 II, III Alopecia Areata NCT03732807; NCT02974868; NCT04006457; NCT04517864
II Rheumatoid Arthritis NCT02969044; NCT04413617
II Ulcerative Colitis NCT02958865
II Crohn’s Disease NCT03395184
TYK2i BMS986165 II, III Psoriasis; Plaque Psoriasis NCT05065762; NCT02931838; NCT03611751; NCT04167462; NCT03924427; NCT04036435; NCT04772079
III Psoriatic Arthritis NCT04908189; NCT04908202
II
Ulcerative Colitis; Colitis, Ulcerative; Granulomatous; Colitis Crohn’s Disease; Crohn’s Enteritis; Granulomatous Enteritis
NCT03934216; NCT04613518; NCT03599622; NCT04877990
II
Systemic Lupus Erythematosus; Lupus Erythematosus, Discoid Lupus Erythematosus; Subacute Cutaneous
NCT03252587; NCT04857034
PF-06826647 II Psoriasis NCT03895372
II Ulcerative Colitis NCT04209556
II Acne Inversa NCT04092452
PF-06835375 II Primary Immune Thrombocytopenia NCT05070845